New appointment at Telormedix
This article was originally published in Scrip
Executive Summary
Telormedix, a clinical-stage Swiss biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, has named Dr Johanna Holldack chief executive officer. She was previously CEO of Borean Pharma, but has also served as chief operation's officer at MediGene, vice-president of global vaccines and therapeutics at Chiron and head of clinical R&D at German Behringwerke.